Discovery Capital Management Decreased Momenta Pharmaceuticals (MNTA) Position By $28.59 Million; Carillion plc (LON:CLLN) Had 0 Bullish Analysts

December 6, 2017 - By Winifred Garcia

Among 14 analysts covering Carillion PLC (LON:CLLN), 0 have Buy rating, 3 Sell and 11 Hold. Therefore 0 are positive. Carillion PLC had 93 analyst reports since July 23, 2015 according to SRatingsIntel. The company was maintained on Tuesday, August 18 by Beaufort Securities. The firm earned “Hold” rating on Thursday, February 9 by Berenberg. Liberum Capital maintained it with “Hold” rating and GBX 200 target in Monday, April 10 report. The rating was downgraded by Peel Hunt to “Add” on Monday, January 25. The firm has “Buy” rating given on Tuesday, September 1 by Liberum Capital. The firm earned “Sell” rating on Friday, February 26 by UBS. Liberum Capital maintained the stock with “Buy” rating in Wednesday, May 4 report. JP Morgan maintained it with “Neutral” rating and GBX 231 target in Thursday, March 2 report. RBC Capital Markets downgraded the stock to “Sector Perform” rating in Friday, January 22 report. The firm has “Add” rating given on Thursday, March 3 by Peel Hunt. See Carillion plc (LON:CLLN) latest ratings:

17/11/2017 Broker: Liberum Capital Rating: Sell New Target: GBX 5.00 Maintain
17/11/2017 Broker: Peel Hunt Rating: Under Review Old Target: GBX 40.00 Under Review
10/11/2017 Broker: Liberum Capital Rating: Sell Maintain
31/10/2017 Broker: Peel Hunt Rating: Reduce New Target: GBX 40.00 Maintain
31/10/2017 Broker: Liberum Capital Rating: Under Review Under Review
13/10/2017 Broker: Peel Hunt Rating: Reduce Old Target: GBX 40.00 New Target: GBX 40.00 Maintain
05/10/2017 Broker: Numis Securities Rating: Hold Old Target: GBX 60.00 New Target: GBX 45.00 Maintain
04/10/2017 Broker: Peel Hunt Rating: Reduce Old Target: GBX 50.00 New Target: GBX 40.00 Maintain
03/10/2017 Broker: Jefferies Rating: Hold Old Target: GBX 80.00 New Target: GBX 45.00 Maintain
03/10/2017 Broker: Liberum Capital Rating: Under Review Under Review

Discovery Capital Management Llc decreased Momenta Pharmaceuticals Inc (MNTA) stake by 59.18% reported in 2017Q2 SEC filing. Discovery Capital Management Llc sold 1.79M shares as Momenta Pharmaceuticals Inc (MNTA)’s stock declined 18.16%. The Discovery Capital Management Llc holds 1.23M shares with $20.84 million value, down from 3.02 million last quarter. Momenta Pharmaceuticals Inc now has $939.60M valuation. The stock decreased 1.21% or $0.15 during the last trading session, reaching $12.3. About 297,165 shares traded. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 54.42% since December 6, 2016 and is uptrending. It has outperformed by 37.72% the S&P500.

Investors sentiment increased to 1.98 in 2017 Q2. Its up 0.47, from 1.51 in 2017Q1. It increased, as 13 investors sold MNTA shares while 33 reduced holdings. 22 funds opened positions while 69 raised stakes. 68.45 million shares or 9.93% more from 62.26 million shares in 2017Q1 were reported. Guggenheim Cap Limited Liability Company holds 42,739 shares. Renaissance Technology Ltd Liability Corporation invested 0.02% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Discovery Capital Mgmt Limited Company Ct stated it has 1.23 million shares or 0.51% of all its holdings. Pub Sector Pension Inv Board has invested 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Moreover, Comerica Bancorporation has 0.01% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Brinker Cap accumulated 21,043 shares or 0.02% of the stock. Raymond James Assocs has invested 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). State Of Tennessee Treasury Department accumulated 0.01% or 62,491 shares. Matarin Cap Mngmt Lc has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 220,913 shares. Blackrock has invested 0.01% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Morgan Stanley stated it has 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Geode Capital Mngmt Limited Company has 620,156 shares. Goldman Sachs Grp Incorporated Inc reported 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Smithfield Trust invested in 0% or 463 shares. Pinebridge Invs LP holds 0% or 8,798 shares.

Among 12 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 4 have Buy rating, 2 Sell and 6 Hold. Therefore 33% are positive. Momenta Pharmaceuticals had 27 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was initiated by Barclays Capital on Monday, November 23 with “Equal-Weight”. The rating was downgraded by Barclays Capital to “Equal-Weight” on Monday, May 22. JP Morgan initiated the shares of MNTA in report on Friday, November 13 with “Overweight” rating. The rating was downgraded by Goldman Sachs to “Neutral” on Thursday, August 6. Leerink Swann maintained it with “Outperform” rating and $25 target in Tuesday, October 13 report. The firm has “Overweight” rating given on Tuesday, January 31 by Barclays Capital. Maxim Group maintained Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) on Thursday, August 3 with “Sell” rating. On Wednesday, October 4 the stock rating was maintained by Barclays Capital with “Equal-Weight”. The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) earned “Hold” rating by Aegis Capital on Tuesday, November 22. The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has “Sell” rating given on Wednesday, September 7 by Maxim Group.

Analysts await Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to report earnings on February, 20. They expect $0.06 EPS, down 90.00% or $0.54 from last year’s $0.6 per share. MNTA’s profit will be $4.58M for 51.25 P/E if the $0.06 EPS becomes a reality. After $-0.44 actual EPS reported by Momenta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -113.64% EPS growth.

Discovery Capital Management Llc increased Xilinx Inc (NASDAQ:XLNX) stake by 177,100 shares to 3.36 million valued at $215.99 million in 2017Q2. It also upped Constellation Brands Inc (NYSE:STZ) stake by 224,300 shares and now owns 588,958 shares. Petroleo Brasileiro Sa Petro was raised too.

The stock decreased 8.96% or GBX 1.5 during the last trading session, reaching GBX 15.25. About 5.67M shares traded. Carillion plc (LON:CLLN) has 0.00% since December 6, 2016 and is . It has underperformed by 16.70% the S&P500.

Carillion plc operates as an integrated support services firm in the United Kingdom, the Middle East and North Africa, Canada, and the rest of the world. The company has market cap of 65.60 million GBP. The firm operates through four divisions: Support Services, Public Private Partnership Projects, Middle East Construction Services, and Construction Services (Excluding the Middle East). It currently has negative earnings. It provides maintenance, facilities management, and energy services to buildings and large property estates, and public and private sectors; infrastructure services for roads, railways, and utility networks, primarily telecommunications and power transmission and distribution sectors; and remote site accommodation and consultancy services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Winifred Garcia




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: